Primer: Innovent Biologics (1801 HK) - Oct 2026
Innovent Biologics has successfully transitioned into sustained profitability, generating FY2025 total revenue of RMB 14.14B (+38.5% YoY) and...
81 Views
Innovent Biologics (1801 HK): Synthetic Expert Call Transcript (07 Oct 2026)
Financial Turnaround Completed: Innovent has crossed the threshold into sustainable, high-scale profitability, recording RMB 1.25 billion in IFRS...
90 Views
Innovent (1801.HK): 1H26 Another Strong Set of Results; Unveiled New 2030 Revenue Target RMB35-40bn
Innovent delievered another strong set of results for 1H26. Mgmt unveiled a new revenue target of RMB35-40bn by 2030. See inside for results call...
100 Views
Innovent Biologics (1801 HK): Unfurling The Growth Momentum, Prospective Pipeline To Take It Forward
Innovent Biologics Inc (1801 HK) 1H26 revenue grew over 45% YoY. The global innovation pipeline is progressing smoothly. Aims to achieve RMB 20B...
114 Views
Innovent Biologics (1801 HK) - 1H26 Beat Bolsters Confidence in Future Growth
The outperformance was driven by strong uptake of mazdutide, PCSK9 mAb, IGF1R, and newly NRDL-included TKIs. We remain confident in management’s...
97 Views